JAMA Netw Open

Patients with eating disorders report perceived benefits from cannabis and psychedelics

July 28, 2025

Study details. This international survey study assessed responses from 7,648 adults with self-reported eating disorders (ED) or disordered eating, recruited via social media, forums, and clinical services between November 2022 and May 2023. The Medications and Other Drugs for Eating Disorders (MED-FED) survey queried recent use of prescription and nonprescription substances and asked participants to rate perceived benefits and harms of each drug.

Results. Among 6,612 respondents (mean age 24.3 years; 94% female), anorexia nervosa was the most common diagnosis (40.8%), followed by bulimia nervosa and binge-eating disorder. Psychiatric comorbidities were prevalent, with depression reported by 65.5%. Cannabis and psychedelics were rated highest for improving ED symptoms. Prescription antidepressants were viewed as beneficial for general mental health but largely ineffective for ED symptoms—except fluoxetine for bulimia and lisdexamfetamine for binge-eating disorder. Alcohol, nicotine, and tobacco were rated as most harmful.

Clinical impact. These findings highlight a disconnect between current pharmacologic treatments and patient-perceived efficacy for ED symptoms. The data support further investigation into the therapeutic potential of cannabis and psychedelics, while reinforcing the need for comprehensive substance use screening in ED care.

Source:

Rodan SC, et al. (2025, July 22). JAMA Netw Open. Prescription and Nonprescription Drug Use Among People With Eating Disorders. https://pubmed.ncbi.nlm.nih.gov/40694346/